Eloxx Pharmaceuticals Q1 2023 Earnings Results & Report

Eloxx Pharmaceuticals EPS Results

• Actual EPS: -$31.68
• Consensus EPS: -$28.05
• Beat/Miss: Missed by -$3.63
• One Year Ago EPS: N/A
• EPS Beat Rate: 3 of last 8 quarters

Eloxx Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Eloxx Pharmaceuticals (OTCMKTS:ELOXD) was a clinical-stage biopharmaceutical company focused on developing therapies for genetic diseases caused by nonsense mutations, which can prevent cells from producing functional proteins. The company’s approach centered on ribosome modulation, a strategy intended to encourage cellular machinery to read through certain premature stop signals in genetic sequences.

Its lead investigational product, ELX-02, was a synthetic aminoglycoside designed to promote nonsense-mutation read-through. Eloxx studied ELX-02 in rare genetic disorders, including cystinosis and cystic fibrosis involving specific nonsense mutations. The company also pursued additional ribosome-modulating compounds, including programs inherited or developed through its combination with Zikani Therapeutics.

Eloxx’s operations were primarily focused on clinical development and collaborations rather than commercialized products. Publicly available information does not establish a current commercial product portfolio, active geographic operations, or current leadership structure for the company. The company’s shares have historically traded under the symbol ELOX and later under the OTC Markets symbol ELOXD.